Flaxseed Consumption and Bone Metabolism in Postmenopausal Women.

NCT ID: NCT03036722

Last Updated: 2018-05-16

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 44 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-05-10
• Study Completion Date: 2018-11-01

Brief Summary

This proposed randomized double blinded, placebo-controlled, parallel trial; with two arms, in females aged 50-70 years, volunteers will be postmenopausal with a BMI between 25-35 kg/m2. This study aims to determine the benefits of phytoestrogen-rich flaxseeds on decreasing bone turnover in postmenopausal women aged over 50 years.

Detailed Description

Osteoporosis affects approximately 1 in 3 women over the age of 50 and accounts for more days spent in hospital than diabetes and breast cancer; amongst women of that age group. Aging, a sedentary lifestyle, a poor diet and smoking are all risk factors. A healthy diet (including food rich in calcium, vitamin D and phytoestrogens) may protect against osteoporosis and risk of fractures. Phytoestrogens in the diet are of putative benefit through and post the menopause. The term phytoestrogens describes a wide variety of plant food derived chemicals having a structure similar to estradiol (oestrogen). The three main classes of phytoestrogens are the isoflavones, the lignans and coumestans. Oil seeds are a good source of lignans, with flaxseeds being particularly rich. Flaxseeds consumption has previously been associated with changes in bone turnover markers in postmenopausal women.

This study therefore is designed to test the hypothesis that consumption of a quantity of flaxseeds achievable in an individual's habitual diet (40g) will induce improvements in bone turnover markers, mediated through the increased circulation of phytoestrogens, in postmenopausal women.

. The study arms are i) A placebo control arm, volunteers consume a placebo 40g porridge (matched for fibre and fat with the flaxseed product) every day over 12 weeks, or ii) 40g of flaxseeds added to 40g porridge daily over a 12 week study period. Adherence to the intervention will be assessed via analysis of concentrations of the mammalian lignans enterolactone and enterodiol in urine. The primary outcome for the study will be changes in markers of bone health. The secondary outcomes for the study will be changes in urinary and plasma androgens. Volunteers will need to attend the Hugh Sinclair Unit of Human Nutrition clinical unit on four occasions to facilitate screening and the study visit.

Volunteers will be required to provide a fasting blood (30ml; 2 tablespoons); 24 hr urine (started the day prior to each study visit) and faecal samples at all 3 study visits (baseline, weeks 6 and 12). As vitamin D status and bone turnover markers are related to bone health, the volunteers will be given the opportunity to undergo an additional measurement of total body composition using dual-energy x-ray absorptiometry (DXA) at baseline and week 12.

Conditions

Bone Loss, Age Realted; Post Menopausal

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Flaxseed porridge group

22 volunteer will be given 80g of a pre prepared porridge meal containing 40 g of ground (flaxseed) to consume daily.

Group Type: EXPERIMENTAL

Flaxseed

Intervention Type: OTHER

Flaxseed is a member of the genus Linum in the family Linaceae. It is a food and fiber crop and it occurs in two basic varieties: brown and yellow or golden (also known as golden linseeds).

Placebo control porridge group

22 volunteer will be given 78.5g preprepared control porridge matched for energy and fat content to consume daily ( Matching food products: 22g MCT (medium chain Triglyceride), 5.5g pure egg white powder, 11g cream of rice).

Group Type: PLACEBO_COMPARATOR

Placebo control porridge

Intervention Type: OTHER

control porridge matched for energy and fat content.

Interventions

Flaxseed

Flaxseed is a member of the genus Linum in the family Linaceae. It is a food and fiber crop and it occurs in two basic varieties: brown and yellow or golden (also known as golden linseeds).

Intervention Type: OTHER

Placebo control porridge

control porridge matched for energy and fat content.

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Postmenopausal women (self reported of final menstrual cycle occurred at least 1 year ago).
• 50-70 years.
• BMI ≥25-35 kg/m2.
• Fasting serum Glucose <7 mmol/l (not diagnosed with diabetes)
• Fasting total cholesterol<7.8 mmol/l and triacylglycerol <2.3 mmol/l.
• Normal liver and kidney function (assessed by measuring total bilirubin, uric acid, creatinine and liver enzymes in the screening blood sample).
• Not having suffered fractures of the hip, wrist or spine, osteoporosis or osteomalacia.
• Blood pressure lower than BP <140/90 mmHg.
• Not having any medical related cause that influencing bone turnover; these include:

• Steroid medical treatment, e.g. 5 mg/ day of prednisolone.
• Abnormal hormonal fluctuation women who self-reported previous diagnoses of thyroid disease, Thyroid hormonal abnormalities, progesterone and oestrogen high level.
• Diagnosed with vitamin D deficiency.
• Not suffering any cardiovascular diseases/ heart diseases e.g. stroke in the past 12 months.
• Not using hormone replacement medicine e.g. oestrogen.
• Not using any calcium or vitamin D supplements during the last 3 months.
• Not suffering from renal or bowel disease.
• No history of alcohol misuse based on self-reported alcohol intake and measurement of liver enzymes in the screening blood sample.

Exclusion Criteria

• Women who became menopausal as the result of surgery (e.x. removal of both ovaries).
• Current smoker.
• Anaemic, haemoglobin ≤ 115g/l or who have abnormal blood biochemistry based on standard clinical cut- offs.
• Have history of food intolerances/allergies (e.g. gluten or dairy) or intolerances (e.g. lactose).
• Received antibiotics in the previous six months.
• Trying to lose weight by following a diet or exercise regimen designed for weight loss, or taking any drug influencing appetite and any drug for weight loss for the last three months.
• Have participated in similar dietary or probiotics-containing product's clinical trials within 3 months before the screening visit.
• Using soy/isoflavone, flax oil and flax supplements.
• Using prebiotic / probiotic during the last 6 months.
• Excessive exercise more than three times a week, including weight bearing exercise.

• Minimum Eligible Age: 50 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: Yes

Sponsors

University of Reading

OTHER

Sponsor Role: lead

Responsible Party

Dr Daniel Commane

Principal Investigator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Mike Proven, PhD

Role: STUDY_CHAIR

Ethics committee Co-ordinator

Locations

University of Reading

Reading, Berkshire, United Kingdom

Site Status: RECRUITING

Countries

United Kingdom

Central Contacts

Daniel M Commane,, PhD

Role: CONTACT

d.m.commane@reading.ac.uk

0118 378 7108

Halah A Hafiz, Mcs

Role: CONTACT

H.A.M.Hafiz@pgr.reading.ac.uk

Facility Contacts

Daniel M Commane, Phd

Role: primary

d.m.commane@reading.ac.uk

References

Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, Lindsay R; National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. Osteoporos Int. 2014 Oct;25(10):2359-81. doi: 10.1007/s00198-014-2794-2. Epub 2014 Aug 15.

Reference Type: BACKGROUND

PMID: 25182228 (View on PubMed)

Foundation, N. O. (2003). Physician's guide to prevention and treatment of osteoporosis, National Osteoporosis Foundation.

Reference Type: BACKGROUND

Hutchins AM, Martini MC, Olson BA, Thomas W, Slavin JL. Flaxseed consumption influences endogenous hormone concentrations in postmenopausal women. Nutr Cancer. 2001;39(1):58-65. doi: 10.1207/S15327914nc391_8.

Reference Type: BACKGROUND

PMID: 11588903 (View on PubMed)

Mei J, Yeung SS, Kung AW. High dietary phytoestrogen intake is associated with higher bone mineral density in postmenopausal but not premenopausal women. J Clin Endocrinol Metab. 2001 Nov;86(11):5217-21. doi: 10.1210/jcem.86.11.8040.

Reference Type: BACKGROUND

PMID: 11701680 (View on PubMed)

Weaver CM, Cheong JM. Soy isoflavones and bone health: the relationship is still unclear. J Nutr. 2005 May;135(5):1243-7. doi: 10.1093/jn/135.5.1243.

Reference Type: BACKGROUND

PMID: 15867312 (View on PubMed)

Go G, Tserendejid Z, Lim Y, Jung S, Min Y, Park H. The association of dietary quality and food group intake patterns with bone health status among Korean postmenopausal women: a study using the 2010 Korean National Health and Nutrition Examination Survey Data. Nutr Res Pract. 2014 Dec;8(6):662-9. doi: 10.4162/nrp.2014.8.6.662. Epub 2014 Sep 15.

Reference Type: BACKGROUND

PMID: 25489406 (View on PubMed)

Other Identifiers

UOReading

Identifier Type: -

Identifier Source: org_study_id